Makalah tentang kemanjuran pengobatan
Diabetes
Clinical trial with control: stem cell therapy outcome related variables.
| Ref | Diagnosis Jumlah Kasus – Usia (Durasi T2DM) | Follow up | Sumber -SC Tipe – Jalur, dosis, Rute, Pengulangan, Interval | Other T2DM Related Therapy | T2DM Related Outcome |
|---|---|---|---|---|---|
| 20 | T2DM1 56 (T), 62 (C) 18-60 y (T=8.6 ± 6.5, C=7.3 ± 6.3) |
1-2-3 mo, every 3 mo until -36 mo | T: Dosis Auto BM-MNC ? DPA, 1x C: ( - ) |
T: D, E, PST, BGM-MA C: D, E, PST, IIT, BGM-MA |
Kadar HbA1c dan C-peptida pada kelompok pengobatan secara signifikan lebih baik dibandingkan nilai sebelum terapi atau kelompok kontrol. Dalam Perawatan: Pemberian insulin dihentikan pada 18 dari 56 pasien; 19/56 pengurangan insulin > 50%, 10/56 pengurangan insulin 15-50%, 9/56 – tidak merespons Pada kelompok kontrol: 40/62 pasien – kebutuhan insulin meningkat > 50%, 22/62 pasien – meningkat 15-45%. |
| dua puluh satu | Diabetes Tipe 2 20 (MNC-HBO), 20 (MNC), 20 (C1=HBO), 20 (C2) 40-65 tahun (2-15 tahun) |
3-6-9-12 mo | Mobil BM-MNC T1: MNC-HBO= 3641,2 ± 1585,4 M T2: MNC = 4012,5 ± 1431,9M DPA – 10 menit 1x |
T and C: D, L, PST, SBGM- IA | Pengurangan dosis insulin pada 12 bulan di T1 dan T2, C1, C2 – tidak berubah Bebas insulin: T1: 1/20, T2: 2/20 Perbaikan pada 12 bulan pada AUC C-Pep T1= T2 > C1, dan AUC Ins T1 dan T2. Kadar HbA1c pada usia 3, 6, 9 dan 12 bulan menurun secara signifikan baik pada T1 maupun T2, tetapi stabil pada C1 dan C2. FBG pada 6, 9 dan 12 bulan – T1 dan T2 -menurun. Peptida C puasa pada 3, 6, 9 dan 12 bulan meningkat secara signifikan pada T1 dan T2, tetapi tetap stabil pada C1 dan C2. |
| dua puluh dua | Diabetes Tipe 2 11 (T), 10 (C) T = 46,5–56 tahun (10–15,5 tahun) C = 52,5–56 tahun (16–21 tahun) |
2-4-6-8-10- 12wk-4-5-6- 9-12 mo | T: otomatis BM- MNC – 290M (220 -380M) C: plasebo, saline SP/DA -1x setelah 12 minggu: PB- GCSF- leucopheresis MNC – 490 (290–730M) C: plasebo, saline –IV-1x |
T dan C: D, L, E, W-SBGM – IA | 12 mo: 50% Insulin reduction -Tr: 9/11 = 82%, -C:0/10, p= 0.002 Insulin red Tr > C (p=0.001, 6 mo), (p=0.004, 12 mo) HbA1C maintenance ( < 7%): Tr 10/11 (91%), C 6/10 (60%), p=0 .167 |
| dua puluh tiga | T2DM 10 (MSC), 10 (MNC), 10 (C) MSC= 36-58 (8-23) MNC= 39.5-50 (8.5-15) C= 43-59 (9-15) |
2-4-8-12- wk-6-9-12 mo | AutoBM-MSC-P4-5 – 1M/kg BW Auto BM-MNC – 1B/pasien C= vitamin B kompleks SPDA – 1x |
T and C: L, PST,D-SBGM- IA | 6/10 (MSC), 6/10 (MNC), 0/10 (C) achieved primary end point: 50% insulin requirement reduction, while maintaining HbA1c
< 7.0% ->significant difference |
| dua puluh empat | T2DM 31 (T), 30(C) 18-60 y (T=8.93±5.67 C=8.3±6.07) |
36 mo | T: Wharton Jelly MSC P4 1M/kg BW C: Larutan garam IV – 2x (interval 4 minggu) |
T and C: D, E, PST, SBGM- MA | Kadar glukosa darah, HbA1c, C-peptida, dan penilaian model homeostasis fungsi sel pulau pankreas meningkat secara signifikan dibandingkan dengan kelompok kontrol. Insiden komplikasi diabetes: Tr – tidak ada peningkatan dibandingkan dengan kondisi awal, C: 4/30 - retinopati diabetik baru, 3/30 neuropati diabetik baru, 3/30 nefropati diabetik baru –> perbedaan yang signifikan secara statistik (Tr vs C, P= 0,007) Pengurangan dosis insulin: Tr: 18/31- pengurangan dosis insulin 50% (di mana 10/31 – bebas insulin dari 3–11 bulan pasca WJMSC, dan durasi bebas insulin 12,5±6,8 bulan), 5/31 - pengurangan 15–50%, dan 8/31 Tidak ada tanggapan Kontrol: 14/30: peningkatan dosis insulin >50%, 16/30: peningkatan dosis insulin 15–45% – 30/30 – tidak merespons |
| dua puluh lima | T2DM + impotence2 7 (T), 3 (C) 57-87 (12-52 y, impo- tence minimal 6 months) |
2 minggu – 11 bulan | T: UCB SC -His tostem, ABO, HLA- ABC, DR, dan jenis kelamin yang cocok – 15M C: injeksi saline – CC -1x |
T and C:PST, D-SBGM-MA | Tr: Blood glucose levels decreased by 2 weeks, and medication dosages were reduced for 4 to 7 months (6/7). HbA1c levels improved after treatment for up to 3 to 4 months (7/7) Reduced insulin dose after 1 month (2/7) Control: no improvement in blood glucose level, HbA1c, and insulin dose. |
| 26 | T2DM 3 15 (T1), 15 (T2), 15 (T3), 3×5 C) T1= 57.7±8.2y (10.8± 7.3y ) T2= 55.3±11.4y (10.2± 5.7y) T3= 57.2 ±6.6y (9.6±4.5y) C= 58.7 ±7.3y (9.8±6.7y) |
12 wk 2y post study |
MPC- P(?) Rexleme- strocel-L – mesoblas Inc, cryo-thawed T1=0,3 M/kg T2=1 M/kg T3=2 M/kg C=plasebo IV- 45 menit 1X |
T and C: L, PST, BGM-RT | Tr: HbA1c – menurun – pada semua titik waktu setelah minggu ke-1, C: sedikit peningkatan HbA1c Target klinis HbA1c < 7% was achieved by 0/15 of Control, 2/15 of T1, 1/15 of T2, and 5/15 of T3 (P < 0.05) |
| 27 | T2DM4 13 (T), 13 (C) 10-58 y (0.5 – 11 y) |
1y | Sel punca hematopoietik hati janin Hu – 35-55 bulan (20% CD34) – dibekukan dan dicairkan Larutan garam (C) IV – 1x |
T and C: BGM-FU | Hingga 1 tahun, tidak ada perbaikan signifikan pada kadar glukosa darah puasa dan peptida C dibandingkan dengan kelompok kontrol. Perbaikan pada – HbA1c hanya pada bulan ke-6: 7,9±1,3 pada kelompok pengobatan vs 7,0 ± 0,86 pada kelompok kontrol (p=0,046). Tidak satu pun dari perawatan tersebut yang bebas insulin. |
Ref = nomor referensi, T2DM = diabetes melitus tipe 2, kontrol pengobatan: 1 pilihan pasien, 2 berturut-turut: 2 Pengobatan – 1 Kontrol, lainnya: acak, 3 buta tunggal multi pusat (18 –AS), 4 = T2DM dan T1DM, T = pengobatan, C = kontrol, y = tahun, MNC = sel mononuklear, HBO = oksigen hiperbarik, MSC = sel punca mesenkimal, mo = bulan, wk = minggu
SC= stem cell, Auto= autologous, BM= bone marrow, ?= data not available, DPA= dorsal pancreatic artery/substitute, M= million, SP/DA= superior pancreatic or duodenal artery, PB= peripheral blood, GCSF= granulocyte colony stimulating factor, IV- intra venous, P= passage, BW= body weight, B= billion, vit.= vitamin, SPDA= superior pancreaticoduode- nal artery, UCB= umbilical cord blood, CC= corpora cavernosa (penile root clamped with a band 30 min), MPC= mesenchymal progenitor cell, cryo= cryopreserved, hu= human, HSC= haematopoeitic stem cell, cryo= cryopreserved,D= diet, E= exercise, PST= previous standard therapy, BGM = blood glucose monitoring, MA= medication adjustment, IIT= insulin intensification therapy, L= lifestyle, SGBM= self blood glucose monitoring, IA= insulin adjustment, W-SGBM= weekly SGBM, D-SGBM= daily SGBM (minimum 5 points/week), RT= rescue therapy using oral anti diabetic agent, except thiazolidinediones in case there was unacceptable hyperglycemia, FU= at follow up
Current Stem Cell Research & Therapy, 2018(13)
Towards Standardized Stem Cell Therapy in Type 2 Diabetes Mellitus: A Systematic Review
Jeanne Adiwinata Pawitan, Zheng Yang, Ying Nan Wu and Eng Hin Lee
[20]Hu J, Li C, Wang L, et al. Long term effects of the implantation of autologous bone marrow mononuclear cells for type 2 diabetes mellitus. Endocr J 2012; 59(11): 1031-9.
[21] Wu Z, Cai J, Chen J, et al. Autologous bone marrow mononuclear cell infusion and hyperbaric oxygen therapy in type 2 diabetes mel- litus: an open-label, randomized controlled clinical trial. Cytother- apy 2014; 16: 258-65
[22] Bhansali A, Asokumar P, Walia R, et al. Efficacy and safety of autologous bone marrow-derived stem cell transplantation in pa- tients with type 2 diabetes mellitus: a randomized placebo- controlled study. Cell Transplant 2014; 23(9): 1075-85.
[23] Bhansali A, Upreti V, Khandelwal N, et al. Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cells Dev 2009; 18(10): 1407-16.
[24] Hu J, Wang Y, Gong H, et al. Long term effect and safety of whar- ton’s jelly-derived mesenchymal stem cells on type 2 diabetes. Ex- perimental and Therapeutic Medicine 2016; 12 (3): 1857-66.
[25] Bahk JY, Jung JH, Han H, Min SK, Lee YS. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant 2010; 8(2): 150-60.
[26] Skyler JS, Fonseca VA, Segal KR, et al. Allogeneic mesenchymal precursor cells in type 2 diabetes: A randomized, placebo- controlled, dose-escalation safety and tolerability pilot study. Dia- betes Care 2015; 38(9): 1742-9.
[27] Ghodsi M, Heshmat R, Amoli M, et al. The effect of fetal liver- derived cell suspension allotransplantation on patients with diabe- tes: first year of follow-up. Acta Med Iran 2012; 50(8): 541-6.